Table 2. DNA Methylation Studies in IBD.
PBMCs, peripheral blood mononuclear cells; TEPP, testis, prostate and placenta expressed; Bcl3, B-cell CLL/lymphoma 3; PPARG, peroxisome proliferator-activated receptor gamma; STAT3, signal transducer and activator of transcription 3 (acute-phase response factor); OSM, oncostatin M; STAT5, signal transducer and activator of transcription 5A; IL12RB, interleukin 12 receptor, beta 1; SOX1, SRY (sex determining region Y)-box 1; COL18A1, collagen, type XVIII, alpha 1; LMTK2, lemur tyrosine kinase 2; CASP2, caspase 2, apoptosis-related cysteine peptidase; TJP2, tight junction protein 2; SMAD2, SMAD family member 2; HCK, HCK proto-oncogene, Src family tyrosine kinase; IL12B, interleukin 12B; LMO1, LIM domain only 1 (rhombotin 1); MAPK13, mitogen-activated protein kinase 13; FASLG, Fas ligand (TNF superfamily, member 6); PRF1, perforin 1 (pore forming protein); S100A13, S100 calcium binding protein A13; RIPK3, receptor-interacting serine-threonine kinase 3; IL-21R, interleukin 21 receptor; BD, Behçet's disease; STAT4, signal transducer and activator of transcription 4; THRAP2, thyroid hormone receptor associated protein 2; FANCC, Fanconi anemia, complementation group C; TNFSF4, tumor necrosis factor (ligand) superfamily, member 4; TNFSF12, tumor necrosis factor (ligand) superfamily, member 12; FUT7, fucosyltransferase 7 (alpha (1,3) fucosyltransferase); CARD9, caspase recruitment domain family, member 9; ICAM3, intercellular adhesion molecule 3; IL8RB, interleukin 8 receptor, beta; EWAS, epigenome-wide methylation association studies; CFI, complement factor I, SPINK4, serine peptidase inhibitor, Kazal type 4; THY1/CD90, Thy-1 cell surface antigen; BGN, biglycan; SERPINA5, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5; TNFSF1A, Tnf tumor necrosis factor; AATK, apoptosis-associated tyrosine kinase; GABRA5, gammaaminobutyric acid (GABA) A receptor, alpha 5; MAPK10, mitogen-activated protein kinase 10; STAT5A, signal transducer and activator of transcription 5A.